Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.
about
( R )- N -Methyl-3-(3′-[ 18 F]fluoropropyl)phenoxy)-3-phenylpropanamine ( 18 F-MFP3) as a potential PET imaging agent for norepinephrine transporterApplication of cross-species PET imaging to assess neurotransmitter release in brainStriatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine UsersDistinct roles of presynaptic dopamine receptors in the differential modulation of the intrinsic synapses of medium-spiny neurons in the nucleus accumbens.Three-dimensional atlas system for mouse and rat brain imaging dataStriatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivityD2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.The simplified reference tissue model with 18F-fallypride positron emission tomography: choice of reference region.High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocolDose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors.Fetal dopamine receptor characteristics assessed in utero.Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.Imaging pancreas in healthy and diabetic rodent model using [18F]fallypride positron emission tomography/computed tomography.Impact of inherent variability and experimental parameters on the reliability of small animal PET data.In the blink of an eye: relating positive-feedback sensitivity to striatal dopamine D2-like receptors through blink rate.Pathway-Specific Dopamine Abnormalities in Schizophrenia.Risk-taking behavior: dopamine D2/D3 receptors, feedback, and frontolimbic activity.Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallyprideDifferential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's diseaseDissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum.The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations.Measuring cigarette smoking-induced cortical dopamine release: A [¹¹C]FLB-457 PET study.Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjectsGray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users.18F-fallypride binding potential in patients with schizophrenia compared to healthy controlsHigh yield and high specific activity synthesis of [18F]fallypride in a batch microfluidic reactor for micro-PET imaging.Titania-catalyzed radiofluorination of tosylated precursors in highly aqueous medium.Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence.Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response.Striatal dopamine D₂/D₃ receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humansPET evidence for a role for striatal dopamine in the attentional blink: functional implicationsEmotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine usersUse of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but Not Methamphetamine-Dependent IndividualsThe distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imagingSynthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging.
P2860
Q24610704-CEA75AC9-48EE-43AF-8294-96531209DEEFQ26865012-D8742958-C057-4DB7-BA70-876F5C5AF969Q28551943-7D35FDDF-8D54-4F78-B809-FD18C0215DA7Q33269872-0F5658D9-85E1-4DB4-BC22-6B3B553E4661Q33381551-CB7A7115-3006-4D3C-85A0-5144D330A27CQ33656355-C76E959F-8F22-45A9-B558-7CA8C6D6E4F3Q33729233-ED6547EF-8C47-4180-877E-A98EE089795AQ33867444-6C443334-11E7-4A6B-A9A9-8E1F13E3A943Q33921691-75884313-4F49-4575-A081-890281F8A73BQ33964443-BC14D4ED-7C5D-4D72-AD44-DB903D022ED2Q34011162-7EC59F2D-FC7C-4958-AB72-5D09D26A5652Q34151747-29107289-9119-47E4-BA9E-76C1D41F4C7EQ34171324-B54807AF-053D-4D23-8561-910DE6BCADD0Q34187457-449E21E8-1C15-4E8E-9996-FEC079A0AB7FQ34283950-CF2A0BDC-9419-4112-990F-7E4DAFE87D3CQ34297928-AE12ED44-7824-4B64-94B3-DFC6996A71EDQ34383509-50D0AD70-12A5-47A2-B349-2477BCBFB0CEQ34527656-98F8BE64-B4F5-4E1F-BC40-E68B4DE8E8DDQ34653399-69015C1A-104C-4736-8F86-88C3F9F688AEQ35024059-C501F088-6124-4C4C-B05B-BC1895D60A65Q35116470-B8197584-0163-4979-AA29-E701203630BDQ35142888-3569228A-FAD6-4E55-9AF7-006EC2FC496BQ35262159-063D73AB-7691-4389-A2C8-0BFCC8C37FE9Q35421107-F8D49719-DE98-4A1A-AB47-955C39B61872Q35423597-1AAF26D8-7184-4E41-9382-50171E446807Q35634676-9E628622-857B-48E9-BE8D-C9B5DF5F2325Q35752862-79A1275F-35F6-48FD-BDEC-8AECD45B9BAAQ35775938-0824FEC3-74AE-4104-BB26-6E9FDC094871Q35797216-0E3BA3E5-6B62-41BA-A214-503B502147E9Q35965848-B0940204-4590-4711-8B4E-549C5F31C3EEQ36075795-82A33DBB-70B7-4B9D-92FB-964140C3FDB6Q36219773-51371358-EC2F-4639-9E9B-D60CB788CA83Q36382450-F4AFFE36-F7B0-49AC-AEED-9FD82347D536Q36453185-F01D8DAF-C592-4928-B805-532566AAA06DQ36507118-BD558208-40AF-44CD-9CD1-9F1514F17D81Q36689502-C0B0B469-6B5F-4571-AF7A-AE4238CD51ADQ36787823-2F7F288F-4FCA-4BD1-9F2F-8C815F83F47FQ36950586-84B440B9-3736-4BD0-95C3-F5094593760FQ37113776-A56932E3-AEBB-4D32-AC31-51057C4C287FQ37117235-2697B282-BAF8-4702-9C7C-265E091E095A
P2860
Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@ast
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@en
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@nl
type
label
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@ast
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@en
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@nl
prefLabel
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@ast
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@en
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@nl
P2093
P1476
Fluorinated benzamide neurolep ...... dopamine D-2 receptor tracer.
@en
P2093
P304
P356
10.1016/0969-8051(94)00117-3
P577
1995-04-01T00:00:00Z